Skip to main content

How Next Generation Sequencing Can Help Accelerate Cell and Gene Therapy Development

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Sarah Lynagh, Ph.D.

    Chief Executive Officer, Fios Genomics
    Sarah has over 20 years’ experience in drug development and commercialisation, predominantly within contract research organisations. She has a degree in Pharmacology and a PhD in Neuropharmacology both from the University of Glasgow, UK.

  • Paul McAdam, Ph.D.

    Head of Next Generation Sequencing, Fios Genomics
    Paul has a background in medical sciences and computational biology. He has a PhD in the molecular epidemiology of infectious disease outbreaks from the Roslin Institute in Edinburgh; his postdoctoral research focused on the statistical and phylogenetic analysis of bacterial populations and led to 13 publications in top tier scientific journals.

  • Gemma Moiset, Ph.D.

    Group Leader Biology, Charles River Laboratories
    Gemma holds a PhD in Life Sciences from the University of Groningen and Zernike Institute for Advanced Materials. Her research focuses on efficacy and toxicity testing of novel drug therapies in human primary cell-based models. Formerly, Dr. Moiset worked in Biotech contributing to the development of monoclonal antibodies against cancer. Prior to that, she was a post-doctoral fellow at the Netherlands Cancer Institute. Dr. Moiset has a combined background in immunology, cellular biology and medicinal chemistry.

February 22, 2022
Tue 12:30 PM EST

Duration 1H 30M

This live web event has ended.

For Technical Support
(888) 705-6002
+1 (858) 201-4136*
*for callers residing outside of the United States